ExQor Technologies

ExQor Technologies is pioneering a novel, two-pronged platform for Alzheimer's disease that integrates diagnosis and treatment. The platform consists of a diagnostic biologic to visualize damaged brain receptors via MRI and a companion therapeutic biologic designed to deliver regenerative proteins directly to those sites, with preclinical data suggesting reversal of neurological damage. An AI-powered software platform personalizes risk assessment and treatment strategy. The company is advancing its lead programs through IND-enabling studies with a regulatory strategy that prioritizes the diagnostic as an entry point.

A unified brain regenerative medicine platform combining: 1) a diagnostic MRI contrast agent that visualizes damaged NMDA receptors, 2) a therapeutic biologic that delivers a protein to those same receptors to repair damage, and 3) an AI-powered software platform for personalized risk assessment, treatment targeting, and real-time efficacy monitoring.

ExQor competes in the Alzheimer's therapeutic space dominated by anti-amyloid antibodies (e.g., lecanemab, donanemab) that slow progression. Its claimed differentiation is reversal of damage via a novel NMDAR-targeting mechanism. It also faces competition from other regenerative and neuroprotective approaches, as well as diagnostic companies developing blood-based or imaging biomarkers. Its integrated 'diagnose-and-treat' platform is a unique angle.